1,033 results on '"Morra, Enrica"'
Search Results
2. Response Assessment in Waldenström’s Macroglobulinaemia
3. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
4. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the “Rete Ematologica Lombarda”
5. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
6. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013
7. Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
8. Response Assessment in Waldenström’s Macroglobulinaemia
9. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
10. Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”
11. Should a Positive Direct Antiglobulin Test Be Considered a Prognostic Predictor in Chronic Lymphocytic Leukemia?
12. Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenström Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
13. Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia
14. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
15. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
16. Clinical Relevance of Bone Marrow Histologic Examination in HIV-Infected Patients
17. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience
18. Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
19. Report From the Sixth International Workshop on Waldenström's Macroglobulinemia
20. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia
21. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
22. Flow cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids
23. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes
24. Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥75 years: A retrospective analysis of the Rete Ematologica Lombarda
25. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma
26. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
27. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
28. Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the “International Working Group” criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience
29. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups
30. Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study
31. Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome
32. A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis
33. Prognostic value of circulating CD34 + cells in myelodysplastic syndromes
34. Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature
35. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
36. Cryoglobulinemia
37. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
38. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta
39. Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes
40. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
41. Splenic marginal zone lymphoma: a prognostic model for clinical use
42. Fludarabine Plus Cyclophosphamide and Rituximab in Waldenstrom Macroglobulinemia: An Effective but Myelosuppressive Regimen to be Offered to Patients With Advanced Disease
43. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
44. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas
45. Treatment of venous thromboembolism in Northern Italy: A population-based study from 2013 to 2018
46. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients
47. Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects
48. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects
49. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
50. Bendamustine: new perspective for an old drug in lymphoproliferative disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.